NTRA's Signatera Gains EU IVDR Certification for Multiple Cancers
Natera's Signatera became the first personalized MRD test for solid tumors to earn EU IVDR certification, supporting broader expansion across Europe.
NTRA - Natera, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$268.90
DETAILS
HIGH:
$310.00
LOW:
$220.00
MEDIAN:
$270.00
CONSENSUS:
$268.90
DOWNSIDE:
0.95%
Stock News
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received certification as a Class C device under the European Union's In Vitro Diagnostic Regulation (IVDR). The IVDR represents one of the world's most rigorous regulatory frameworks for in vitro diagnostic medical devices, replacing the outgoing In Vitro Diagnostic Medical Devices Directive (IVDD). To obtain certification, the Signatera platf.
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in JAMA Oncology, evaluating the utility of Signatera, its personalized molecular residual disease (MRD) test, in patients with resected colorectal liver metastases (CRLM). The data was also presented as an oral presentation at the 2026 European Society for Medical Oncology Gastrointestinal (ESMO GI) Congress. The liver is the most com.
NTRA & Aveta Partner to Advance MRD-Guided Trial in Head & Neck Cancer
Natera's Aveta partnership brings Signatera into a global Phase 3 head and neck cancer trial to assess MRD and treatment response.
Natera, Aveta partner on late-stage head and neck cancer trial
Genetic testing firm Natera and cancer drug developer Aveta Biomics said on Monday they have partnered on a late-stage study of an experimental therapy for head and neck cancer, in a bid to improve how patients' response to treatment is monitored.
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
AUSTIN, Texas & BEDFORD, Mass.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Aveta Biomics, Inc., a clinical-stage immuno-oncology company advancing first-in-class oral immunotherapies for solid tumors, today announced a strategic partnership supporting AVTA 30-01, Aveta's global Phase 3 registrational clinical trial evaluating APG-157 in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) (NCT07667296).APG.
NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in Japan
Natera's Signatera gains Japan PMDA approval for CRC, marking the country's first approved MRD test and advancing its global expansion.
Natera (NTRA) Stock Jumps 10.7%: Will It Continue to Soar?
Natera (NTRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
AUSTIN, Texas & IRVINE, Calif.--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage biotechnology company developing immune-modulating therapies for the management and treatment of life-threatening conditions, today announced a strategic partnership to incorporate Natera's Prospera kidney transplant assessment test into Eledon's planned Phase 3 clinical trial of tegoprubart, an in.
Natera Secures Landmark Japan Nod For Signatera In Colorectal Cancer
Natera Inc. (NASDAQ:NTRA) said Japan's Ministry of Health, Labour and Welfare approved its Signatera molecular residual disease (MRD) test for patients with colorectal cancer in the adjuvant setting, making it the first PMDA-approved MRD test in the country.
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA). This approval supports the use of Signatera for patients with colorectal cancer (CRC) in the adjuvant setting and makes Signatera the first PMDA-approved MRD test in Japan. Natera expects to commercially launch Signatera for CRC in Japan by the end of 2.
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib
Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed multiplex PCR circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) testing in the treatment algorithm for patients with MIBC.The updated guidelines state that the Panel “recommends the conside.
Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced its robust scientific presence at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026. The company and its collaborators will share 21 presentations, including seven oral presentations, highlighting the utility of the Prospera test to inform risk assessment and long-term graft monitoring across kidney, heart, lung, and multi-organ transp.
Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRC
Natera teams with CytoDyn to track ctDNA in CLOVER Phase 2, using Signatera to map leronlimab response in metastatic colorectal cancer.
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
AUSTIN, Texas & VANCOUVER, Wash.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced a strategic collaboration to evaluate circulating tumor DNA (ctDNA) dynamics and generate real-world molecular insi.
Here's Billionaire Stanley Druckenmiller's Top Holding (Hint: It's Not Alphabet or Nvidia)
Most investors' portfolios hold at least a couple of the market's biggest companies, just because these names are best-known to most investors. These crowded trades in already-massive companies, however, can mean their potential upside is limited.
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the appointments of Thomas Lynch, M.D., and Eric Rubin, M.D., to the Company's board of directors. “Tom and Eric have helped lead some of the most important advances in modern oncology, and we are thrilled to welcome them to the Board,” said Matthew Rabinowitz, Ph.D., co-founder of Natera and executive chairman of the board. “Their deep expertise across evidence.
Price Targets
Natera price target raised to $310 from $250 at Morgan Stanley
$310.00
(was $274.39)
Morgan Stanley
Natera price target raised to $300 from $270 at Evercore ISI
$300.00
(was $281.26)
Evercore ISI
Natera price target raised to $290 from $270 at Guggenheim
$290.00
(was $261.91)
Subbu Nambi
·
Guggenheim
Natera price target raised to $275 from $270 at BTIG
$275.00
(was $260.72)
BTIG
Natera price target lowered to $260 from $280 at Barclays
$260.00
(was $234.76)
UBS
Natera (NTRA) PT Raised to $270 at BTIGMember Login
$270.00
(was $234.76)
BTIG
RBC Capital Starts Natera (NTRA) at Outperform
$275.00
(was $219.23)
Dan Leonard
·
RBC Capital
Goldman Sachs Starts Natera (NTRA) at Neutral
$245.00
(was $222.10)
Evie Koslosky
·
Goldman Sachs
Natera price target raised to $249 from $240 at Piper Sandler
$249.00
(was $199.14)
Piper Sandler
Natera price target raised to $265 from $257 at Baird
$265.00
(was $201.13)
Robert W. Baird
Natera price target raised to $270 from $250 at Evercore ISI
$270.00
(was $200.20)
Evercore ISI
Natera price target raised to $220 from $215 at Wells Fargo
$220.00
(was $219.82)
Brandon Couillard
·
Wells Fargo
Natera price target raised to $270 from $230 at Guggenheim
$270.00
(was $230.65)
Guggenheim
Natera price target raised to $285 from $260 at Canaccord
$285.00
(was $231.96)
Canaccord Genuity
Natera price target raised to $205 from $190 at Wells Fargo
$205.00
(was $231.88)
Wells Fargo
Natera price target raised to $270 from $230 at Barclays
$270.00
(was $231.88)
Barclays
Natera assumed with an Overweight at Morgan Stanley
$265.00
(was $234.25)
Morgan Stanley
Natera price target raised to $280 from $218 at UBS
$280.00
(was $213.65)
UBS
Natera upgraded to Neutral from Underperform at BNP Paribas Exane
$172.00
(was $192.35)
Navann Ty
·
BNP Paribas
Natera initiated with an Equal Weight at Wells Fargo
$175.00
(was $181.11)
Brandon Couillard
·
Wells Fargo